With over 25 years of experience in the medical device industry, Tim Moran is the President and CEO of Avertix Medical, a company that is commercializing a class III, implantable device for cardiovascular disease management. The Guardian System is the first and only FDA-approved and CMS reimbursed device that detects heart attacks in real-time, including silent and asymptomatic attacks, providing life-saving alerts to patients and healthcare professionals.
Effective August 1, 2024, Tim was appointed to the Board of Directors for Adagio Medical, (Nasdaq: ADGM) and serves on the Audit and Compensation Committees.
From April 2023 through August 2024, Tim served as Chairman, Board of Directors, at Motus GI (Nasdaq: MOTS), a company that he previously led as CEO from product development to commercialization, achieving multiple FDA clearances, EU MDR/CE, and key clinical milestones. He established the go-to-market strategy, hired the direct commercial team, and secured more than $70M in multiple financing rounds.
Tim started his career and spent 19 years at Covidien, which was acquired by Medtronic in 2014, and held a series of commercial leadership roles, culminating in his position as Global VP & General Manager for the $1.4B Patient Care & Safety Unit, which was later acquired by Cardinal Health. Following Covidien, Tim was named President at ConvaTec, a UK based leader in chronic disease management, having responsibility for the $800M Americas business. Tim played a key role in helping take ConvaTec public on the London Stock Exchange, LSE, in 2016.
Tim is passionate about bringing innovative and disruptive technologies to the market that can improve the lives of millions of patients. He has a proven track record of driving robust product development, building strategic partnerships, and creating value for shareholders.
With over 25 years of experience in the medical device industry, Tim Moran is the President and CEO of Avertix Medical, a company that is commercializing a class III, implantable device for cardiovascular disease management. The Guardian System is the first and only FDA-approved and CMS reimbursed device that detects heart attacks in real-time, including silent and asymptomatic attacks, providing life-saving alerts to patients and healthcare professionals.
Effective August 1, 2024, Tim was appointed to the Board of Directors for Adagio Medical, (Nasdaq: ADGM) and serves on the Audit and Compensation Committees.
From April 2023 through August 2024, Tim served as Chairman, Board of Directors, at Motus GI (Nasdaq: MOTS), a company that he previously led as CEO from product development to commercialization, achieving multiple FDA clearances, EU MDR/CE, and key clinical milestones. He established the go-to-market strategy, hired the direct commercial team, and secured more than $70M in multiple financing rounds.
Tim started his career and spent 19 years at Covidien, which was acquired by Medtronic in 2014, and held a series of commercial leadership roles, culminating in his position as Global VP & General Manager for the $1.4B Patient Care & Safety Unit, which was later acquired by Cardinal Health. Following Covidien, Tim was named President at ConvaTec, a UK based leader in chronic disease management, having responsibility for the $800M Americas business. Tim played a key role in helping take ConvaTec public on the London Stock Exchange, LSE, in 2016.
Tim is passionate about bringing innovative and disruptive technologies to the market that can improve the lives of millions of patients. He has a proven track record of driving robust product development, building strategic partnerships, and creating value for shareholders.
17011 Beach Blvd, Suite 500 Huntington Beach, CA 92647
714-847-3540© 2025 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy